Jun 25 |
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
|
Jun 25 |
IGC Pharma GAAP EPS of -$0.22 in-line, revenue of $1.35M beats by $0.11M
|
Jun 24 |
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
|
Jun 18 |
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
|
Jun 10 |
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
|
May 28 |
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
|
May 21 |
IGC Pharma to Attend BIO International Convention 2024
|
Apr 16 |
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
|
Apr 9 |
IGC Pharma Adds Advisor in Artificial Intelligence
|
Mar 26 |
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
|